38.60
+0.17(+0.44%)
Currency In USD
| Previous Close | 38.43 |
| Open | 38.45 |
| Day High | 38.81 |
| Day Low | 38.2 |
| 52-Week High | 41.24 |
| 52-Week Low | 24.46 |
| Volume | 4.57M |
| Average Volume | 4.05M |
| Market Cap | 16.76B |
| PE | 22.06 |
| EPS | 1.75 |
| Moving Average 50 Days | 38.28 |
| Moving Average 200 Days | 35.47 |
| Change | 0.17 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $956.63 as of December 21, 2025 at a share price of $38.6. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 3 years ago, it would be worth $1,030.98 as of December 21, 2025 at a share price of $38.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
GlobeNewswire Inc.
Dec 16, 2025 12:15 PM GMT
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Nel
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
GlobeNewswire Inc.
Dec 04, 2025 12:10 PM GMT
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
GlobeNewswire Inc.
Nov 04, 2025 12:15 PM GMT
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310